|
| 37985388 | Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia. | Cancer | 2024 |
| 37985388 | Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia. | Cancer | 2024 |
| 36628921 | Comparison of design methods for a safety run-in phase of a phase II clinical trial. | Clin Trials | 2023 |
| 35838057 | IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. | Pediatr Hematol Oncol | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 37019972 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | Nat Commun | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 37390387 | Reply to Z.R. McCaw et al. | J Clin Oncol | 2023 |
| 36634304 | CREBBP alterations are associated with a poor prognosis in de novo AML. | Blood | 2023 |
| 36628921 | Comparison of design methods for a safety run-in phase of a phase II clinical trial. | Clin Trials | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 37228094 | Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. | J Natl Cancer Inst | 2023 |
| 37496113 | Information fraction estimation: Strategies for a phase 3 non-inferiority maximum duration design with time to event outcome. | Pharm Stat | 2023 |
| 37480164 | Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. | Pediatr Blood Cancer | 2023 |
| 37480164 | Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. | Pediatr Blood Cancer | 2023 |
| 37496113 | Information fraction estimation: Strategies for a phase 3 non-inferiority maximum duration design with time to event outcome. | Pharm Stat | 2023 |
| 35838057 | IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. | Pediatr Hematol Oncol | 2023 |
| 37390387 | Reply to Z.R. McCaw et al. | J Clin Oncol | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 37019972 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | Nat Commun | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 37228094 | Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. | J Natl Cancer Inst | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36634304 | CREBBP alterations are associated with a poor prognosis in de novo AML. | Blood | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 34719869 | Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA. | Proteomics Clin Appl | 2022 |
| 35688939 | A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. | Leukemia | 2022 |
| 35870472 | Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. | Lancet Haematol | 2022 |
| 35868503 | Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients. | Contemp Clin Trials | 2022 |
| 35363510 | Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. | J Clin Oncol | 2022 |
| 36198128 | Automated Ascertainment of Typhlitis From the Electronic Health Record. | JCO Clin Cancer Inform | 2022 |
| 36123353 | Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. | Nat Commun | 2022 |
| 35353553 | Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. | J Clin Oncol | 2022 |
| 36525620 | Safety and Acceptability of Three Ablation Treatments for High-Grade Cervical Precancer: Early Data From a Randomized Noninferiority Clinical Trial. | JCO Glob Oncol | 2022 |
| 34990262 | Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. | J Clin Oncol | 2022 |
| 34855461 | CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. | J Clin Oncol | 2022 |
| 34719869 | Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA. | Proteomics Clin Appl | 2022 |
| 35021602 | Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group study. | Haematologica | 2022 |
| 35158884 | Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. | Cancers (Basel) | 2022 |
| 34762093 | Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. | JAMA Oncol | 2022 |
| 35176137 | Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. | Blood Cancer Discov | 2022 |
| 35322524 | Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance? | Pediatr Blood Cancer | 2022 |
| 34472213 | Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2022 |
| 35353553 | Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. | J Clin Oncol | 2022 |
| 35363510 | Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. | J Clin Oncol | 2022 |